Madhu Chaudhry
Expertise in
17
conditions

Dr. Madhu Chaudhry

Oncology | Hematology
Scotland Cancer Treatment Center (Duke Cancer Network)
500 Lauchwood Dr, 
Laurinburg, NC 
Accepting New Patients
Offers Telehealth
Referral may be required
Before you request
Expertise in
17
conditions
Scotland Cancer Treatment Center (Duke Cancer Network)
500 Lauchwood Dr, 
Laurinburg, NC 

Overview

My primary focus is to deliver high-quality and compassionate care to patients. I aim to treat all my patients like I would want my own family members to be treated. My grandmother died of gall bladder cancer. I accompanied her to all her appointments and that experience led me to choose the field of hematology-oncology. Trust between patients and their oncologists is paramount, and I strive to be my patients' trusted friend. Open discussion of all available treatment options and active participation of the patient is extremely important to me. Making patients aware of all evidence-based treatments and ongoing clinical trials before we create a mutually agreed upon treatment plan is crucial. I am always available to discuss various issues that may arise as part of a patient's treatment plan.

Dr. Chaudhry is highly rated in 17 conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Paget Disease of the Breast, Relapsed Refractory Multiple Myeloma (RRMM), and Multiple Myeloma.

Dr. Chaudhry is board certified in American Board Of Internal Med, Medical Oncology , American Board Of Internal Med, Hematology, and American Board Of Internal Med, Internal Medicine . She is actively involved in clinical research, co-authoring 1 peer reviewed article and participating in 11 clinical trials. Dr. Chaudhry is currently accepting new patients.

Specialties

Oncology
Hematology

Licenses

Internal Medicine in NC

Board Certifications

American Board Of Internal Med, Medical Oncology
American Board Of Internal Med, Hematology
American Board Of Internal Med, Internal Medicine

Fellowships

Hematology and Oncology, University of Maryland

Hospital Affiliations

Scotland Memorial Hospital
Southeastern Regional Medical Center

Languages Spoken

English
Hindi
Punjabi

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Absolute Total Care South Carolina
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
Aetna
  • EPO
  • HMO
  • POS
  • PPO
Ambetter
  • EPO
  • HMO
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Piedmont
  • HMO
  • POS
Trillium
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

Scotland Cancer Treatment Center (Duke Cancer Network)
500 Lauchwood Dr, Laurinburg, NC 28352
Other Locations
Maria Parh Cancer Center (Duke Cancer Network)
566 Ruin Creek Rd, Henderson, NC 27536

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 02, 2026
Intervention Type: Other
Study Phase: Phase 3
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: August 31, 2026
Intervention Type: Radiation, Procedure
Study Phase: Phase 3
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Exemestane, Letrozole, Systemic Chemotherapy
Study Phase: Phase 3
A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer
A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Other, Procedure, Drug
Study Drugs: Entinostat, Exemestane, Goserelin, Goserelin Acetate
Study Phase: Phase 3
A Phase IIR/III Trial of Standard of Care Therapy With or Without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer
A Phase IIR/III Trial of Standard of Care Therapy With or Without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer
Enrollment Status: Completed
Publish Date: July 10, 2026
Intervention Type: Radiation, Procedure
Study Phase: Phase 2/Phase 3
A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
Enrollment Status: Terminated
Publish Date: May 29, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Atezolizumab, Paclitaxel, Pertuzumab, Trastuzumab
Study Phase: Phase 3
Phase II Randomized Placebo-Controlled Trial of Cisplatin With or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer, With or Without Brain Metastases
Phase II Randomized Placebo-Controlled Trial of Cisplatin With or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer, With or Without Brain Metastases
Enrollment Status: Completed
Publish Date: April 08, 2026
Intervention Type: Other, Drug
Study Drugs: Cisplatin, Veliparib
Study Phase: Phase 2
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 10, 2026
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
BYLieve: A Phase II, Multicenter, Open-label, Three-cohort, Non- Comparative Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole in Patients With PIK3CA Mutant, Hormone Receptor (HR) Positive, HER2-negative Advanced Breast Cancer (aBC), Who Have Progressed on or After Prior Treatments
BYLieve: A Phase II, Multicenter, Open-label, Three-cohort, Non- Comparative Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole in Patients With PIK3CA Mutant, Hormone Receptor (HR) Positive, HER2-negative Advanced Breast Cancer (aBC), Who Have Progressed on or After Prior Treatments
Enrollment Status: Completed
Publish Date: January 13, 2026
Intervention Type: Drug
Study Drugs: Alpelisib, Fulvestrant, Letrozole, Goserelin, Leuprolide
Study Phase: Phase 2
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Enrollment Status: Completed
Publish Date: October 24, 2023
Intervention Type: Drug
Study Drugs: Ribociclib, Letrozole, Goserelin, Leuprolide
Study Phase: Phase 3
View 9 Less Clinical Trials

1 Total Publications

The Effects of a Remote-based Weight Loss Program on Adipocytokines, Metabolic Markers, and Telomere Length in Breast Cancer Survivors: the POWER-Remote Trial.
The Effects of a Remote-based Weight Loss Program on Adipocytokines, Metabolic Markers, and Telomere Length in Breast Cancer Survivors: the POWER-Remote Trial.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: September 20, 2019
Similar Doctors
Expertise in
44
conditions
Dr. Raghava R. Induru
Hematology | Oncology
Expertise in
44
conditions
Dr. Raghava R. Induru
Hematology | Oncology
Referral may be required
Before you request

Atrium Health Levine Cancer Institute, A Facility Of Carolinas Medical Center

945-B N. 5th St., 
Albemarle, NC 
 (58.3 miles away)
980-323-7790
Languages Spoken:
English, Hindi, Telugu
See accepted insurances
Accepting New Patients
Offers Telehealth

Raghava Induru is a Hematologist and an Oncologist practicing medicine in Albemarle, North Carolina. Dr. Induru is highly rated in 44 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Pleuropulmonary Blastoma, Chronic Lymphocytic Leukemia (CLL), and Small Cell Lung Cancer (SCLC). Dr. Induru is board certified in American Board Of Family Medicine, Hospice And Palliative Medicine, American Board Of Internal Medicine, and American Board Of Internal Medicine, Medical Oncology. Dr. Induru is currently accepting new patients.

Expertise in
20
conditions
Dr. Kenneth I. Fink
Hematology | Oncology
Expertise in
20
conditions
Dr. Kenneth I. Fink
Hematology | Oncology
Referral may be required
Before you request

Columbus Regional Healthcare System

500 Jefferson St., 
Whiteville, NC 
 (52.5 miles away)
910-642-8011
Languages Spoken:
English, French, German
See accepted insurances
Accepting New Patients
Offers Telehealth

Kenneth Fink is a Hematologist and an Oncologist practicing medicine in Whiteville, North Carolina. Dr. Fink is highly rated in 20 conditions, according to our data. His clinical expertise encompasses Colorectal Cancer, Familial Colorectal Cancer, Lynch Syndrome, Immune Thrombocytopenic Purpura (ITP), and Bone Marrow Aspiration. Dr. Fink is board certified in American Board Of Internal Medicine, Hematology, American Board Of Internal Medicine, and American Board Of Internal Medicine, Medical Oncology. Dr. Fink is currently accepting new patients.

Expertise in
50
conditions
Dr. Gregory M. Brouse
Hematology | Oncology
Expertise in
50
conditions
Dr. Gregory M. Brouse
Hematology | Oncology
Referral may be required
Before you request

Atrium Health Levine Cancer Institute

1550 Faulk St., Suite 1500, 
Monroe, NC 
 (61.7 miles away)
980-442-0430
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Gregory Brouse is a Hematologist and an Oncologist practicing medicine in Monroe, North Carolina. Dr. Brouse is highly rated in 50 conditions, according to our data. His clinical expertise encompasses Paget Disease of the Breast, Lung Cancer, Pleuropulmonary Blastoma, Inflammatory Breast Cancer, and Bone Marrow Aspiration. Dr. Brouse is board certified in American Board Of Internal Medicine and American Board Of Internal Medicine, Medical Oncology. Dr. Brouse is currently accepting new patients.

Frequently Asked Questions about Dr. Madhu Chaudhry

How do I make an appointment with Dr. Madhu Chaudhry?

You can book an appointment with Dr. Madhu Chaudhry by calling their office at 910-291-7630. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Madhu Chaudhry a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Madhu Chaudhry is classified as an Distinguished expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Madhu Chaudhry specialize in?

While Dr. Madhu Chaudhry is a Oncology, they have specific expertise in Breast Cancer, Paget Disease of the Breast, and Relapsed Refractory Multiple Myeloma (RRMM). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Madhu Chaudhry participate in research or clinical trials?

Yes. Dr. Madhu Chaudhry has published 1 articles and abstracts on conditions like Breast Cancer. You can view a list of Dr. Madhu Chaudhry's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Madhu Chaudhry accept my insurance?

Dr. Madhu Chaudhry accepts most major insurance plans, including Absolute Total Care South Carolina and Aetna. We recommend calling the office directly at 910-291-7630 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Chaudhry's expertise for a condition
ConditionClose
    View All 15 Advanced Conditions
    View All 60 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile